578 related articles for article (PubMed ID: 24893821)
21. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
Pietruck F; Budde K; Salvadori M; Sollinger H; Bourbigot B; Gentil MA; Oppenheimer F
Clin Transplant; 2007; 21(1):117-25. PubMed ID: 17302600
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
27. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
28. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
[TBL] [Abstract][Full Text] [Related]
29. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
[TBL] [Abstract][Full Text] [Related]
30. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
Martinez-Mier G; Salazar-Ramirez A
Transplant Proc; 2016 Mar; 48(2):588-95. PubMed ID: 27110009
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
[TBL] [Abstract][Full Text] [Related]
32. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
[TBL] [Abstract][Full Text] [Related]
33. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
[TBL] [Abstract][Full Text] [Related]
34. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
36. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
[TBL] [Abstract][Full Text] [Related]
37. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
Budde K; Knoll G; Curtis J; Kahana L; Pohanka E; Seifu Y; Neumayer HH
Transplant Proc; 2005 Mar; 37(2):912-5. PubMed ID: 15848573
[TBL] [Abstract][Full Text] [Related]
39. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO
Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies.
Legendre C; Cohen D; Zeier M; Rostaing L; Budde K
Transplant Proc; 2007 Jun; 39(5):1386-91. PubMed ID: 17580145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]